Biosimilars Market: By Drug Class (Monoclonal Antibodies, Recombinant Hormones, Recombinant Growth Factors, Immunomodulators, Anti-Inflammatory Agents, and Others), By Application (Oncology, Blood Disorders, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Diabetes, and Others), By Manufacturing Type (Captive and Out-sourcing), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Biosimilars Market size was valued at USD 14.9 billion in 2022, and is expected to be USD 45.4 billion by 2029 and is poised to grow at a CAGR of 24.6% from 2023 to 2029. The rising frequency of chronic diseases, as well as increased demand for biosimilars due to their cost-effectiveness, are driving market expansion. Regulatory approvals and other rules in various countries that encourage the use of biosimilars are also a major driving force in the biosimilars industry. However, during the projection period, the challenges of biosimilar development and production, as well as pushback from reference biologic manufacturers, are projected to limit the market's expansion. A factor that contributes to these high costs is a lack of economies of scale due to lesser demand. Furthermore, the absence of regulatory guidelines, consumer brand preferences, physician reluctance to prescribe biosimilars, and the high capital necessary for research and development are all impeding the growth of the biosimilars industry. Because of the advantageous government rules in this region, countries from the European Union currently dominate the market.

The biosimilars market in North America is now hampered by weak and flexible rules. However, given to the shifting off-patent environment, biosimilars applications in autoimmune and chronic diseases have the most potential. The biopharmaceutical business is heavily reliant on modern technologies for various development and manufacturing processes. These technologies have become a requirement for all biopharmaceutical and healthcare research operations. Monoclonal Antibodies (MAb) Technology, Recombinant DNA Technology (rDNA Technology), Nuclear Magnetic Resonance (NMR) Technology, Chromatography, Electrophoresis, Mass Spectrometry, Western Blotting, and Bioassay are only a few of the important technologies addressed in the paper.

Global Biosimilars Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

24.6%

Largest Market

Europe

Fastest Growing Market

Asia Pacific
Biosimilars Market Dynamics

biosimilars market is gaining traction in recent times owing to its cost-effective pricing in comparison with patented or branded biologics, which are generally priced higher than biologics. The adoption of cost-effective biosimilars is rising in different healthcare setups across the developed and developing countries to curtail the growing pressure on healthcare budgets. The introduction of biosimilars has even led to improved access to the premium-priced biopharmaceuticals in developing and underdeveloped markets with lesser costs. Moreover, favourable government policies to promote cost-effective biosimilars expected to drive market revenue growth over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Biosimilars Market Segmentation

By Drug Class
  • Monoclonal Antibodies
  • Recombinant Hormones
  • Recombinant Growth Factors
  • Immunomodulators
  • Anti-Inflammatory Agents
  • Others
By Application
  • Oncology
  • Blood Disorders
  • Autoimmune Diseases
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Diabetes
  • Others
By Manufacturing Type
  • Captive
  • Out-sourcing
distribution channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The biosimilars market size was valued USD 14.9 billion in 2022

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Executive Summary

  2. Global Biosimilar Market Introduction

    • 2.1. Global Biosimilar Market Taxonomy
    • 2.2. Global Biosimilar Market Definitions
      • 2.2.1. Drug Class
      • 2.2.2. Manufacturing Type
      • 2.2.3. Application
      • 2.2.4. By Region
  3. Global Biosimilar Market Dynamics

    • 3.1. Drivers
    • 3.2. Restraints
    • 3.3. Opportunities/Unmet Needs of the Market
    • 3.4. Trends
    • 3.5. Product Landscape
    • 3.6. New Product Launches
    • 3.7. Impact of COVID-19 on the Market
    • 3.8. Unique Selling Proposition (USP)
    • 3.9. Macro Trends
  4. Global Biosimilar Market Analysis, 2018-2022 and Forecast 2023-2029

    • 4.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
    • 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    • 4.3. Market Opportunity Analysis
  5. Global Biosimilar Market By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 5.1. Monoclonal Antibodies
      • 5.1.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 5.1.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 5.1.3. Market Opportunity Analysis
    • 5.2. Recombinant Hormones
      • 5.2.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 5.2.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 5.2.3. Market Opportunity Analysis
    • 5.3. Recombinant Growth Factors
      • 5.3.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 5.3.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 5.3.3. Market Opportunity Analysis
    • 5.4. Immunomodulators
      • 5.4.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 5.4.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 5.4.3. Market Opportunity Analysis
    • 5.5. Anti-Inflammatory Agents
      • 5.5.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 5.5.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 5.5.3. Market Opportunity Analysis
    • 5.6. Others
      • 5.6.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 5.6.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 5.6.3. Market Opportunity Analysis
  6. Global Biosimilar Market By Manufacturing Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 6.1. Captive
      • 6.1.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 6.1.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 6.1.3. Market Opportunity Analysis
    • 6.2. Outsourcing
      • 6.2.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 6.2.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 6.2.3. Market Opportunity Analysis
  7. Global Biosimilar Market By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 7.1. Oncology
      • 7.1.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 7.1.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 7.1.3. Market Opportunity Analysis
    • 7.2. Blood Disorders
      • 7.2.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 7.2.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 7.2.3. Market Opportunity Analysis
    • 7.3. Autoimmune Diseases
      • 7.3.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 7.3.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 7.3.3. Market Opportunity Analysis
    • 7.4. Endocrine Diseases
      • 7.4.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 7.4.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 7.4.3. Market Opportunity Analysis
    • 7.5. Infectious Diseases
      • 7.5.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 7.5.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 7.5.3. Market Opportunity Analysis
    • 7.6. Diabetes
      • 7.6.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 7.6.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 7.6.3. Market Opportunity Analysis
    • 7.7. Others
      • 7.7.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 7.7.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 7.7.3. Market Opportunity Analysis
  8. Global Biosimilar Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 8.1. North America
      • 8.1.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 8.1.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 8.1.3. Market Opportunity Analysis
    • 8.2. Europe
      • 8.2.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 8.2.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 8.2.3. Market Opportunity Analysis
    • 8.3. Asia Pacific (APAC)
      • 8.3.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 8.3.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 8.3.3. Market Opportunity Analysis
    • 8.4. Latin America
      • 8.4.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 8.4.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 8.4.3. Market Opportunity Analysis
    • 8.5. Middle East and Africa (MEA)
      • 8.5.1. Market Analysis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
      • 8.5.2. Y-o-Y Growth Analysis (%) and Market Share Analysis (%)
      • 8.5.3. Market Opportunity Analysis
  9. Global Biosimilar Market - Opportunity Analysis Index, By Manufacturing Type, Drug Class, Application, and Region, 2023-2029

  10. North America Biosimilar Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 10.1. Drug Class Analysis
    • 10.2. Manufacturing Type Analysis
    • 10.3. Application Analysis
    • 10.4. Country Analysis
      • 10.4.1. United States of America (USA)
      • 10.4.2. Canada
  11. Europe Biosimilar Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 11.1. Drug Class Analysis
    • 11.2. Manufacturing Type Analysis
    • 11.3. Application Analysis
    • 11.4. Country Analysis
      • 11.4.1. Germany
      • 11.4.2. France
      • 11.4.3. Italy
      • 11.4.4. United Kingdom (UK)
      • 11.4.5. Spain
      • 11.4.6. Rest of EU
  12. Asia Pacific (APAC) Biosimilar Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 12.1. Drug Class Analysis
    • 12.2. Manufacturing Type Analysis
    • 12.3. Application Analysis
    • 12.4. Country Analysis
      • 12.4.1. China
      • 12.4.2. India
      • 12.4.3. Australia and New Zealand (ANZ)
      • 12.4.4. Japan
      • 12.4.5. Rest of APAC
  13. Latin America Biosimilar Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 13.1. Drug Class Analysis
    • 13.2. Manufacturing Type Analysis
    • 13.3. Application Analysis
    • 13.4. Country Analysis
      • 13.4.1. Brazil
      • 13.4.2. Mexico
      • 13.4.3. Rest of LA
  14. Middle East and Africa (MEA) Biosimilar Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)

    • 14.1. Drug Class Analysis
    • 14.2. Manufacturing Type Analysis
    • 14.3. Application Analysis
    • 14.4. Country Analysis
      • 14.4.1. GCC Countries
      • 14.4.2. South Africa
      • 14.4.3. Rest of MEA
  15. Competition Landscape

    • 15.1. Strategic Dashboard of Top Market Players
    • 15.2. Company Profiles
      • 15.2.1. Amgen Inc. (U.S.)
      • 15.2.2. Biocon Ltd. (India)
      • 15.2.3. Celltrion, Inc. (South Korea)
      • 15.2.4. Dr. Reddy’s Laboratories Ltd. (India)
      • 15.2.5. F. Hoffmann-La Roche Ltd. (Switzerland)
      • 15.2.6. Pfizer Inc. (U.S.)
      • 15.2.7. Samsung Bioepis (South Korea)
      • 15.2.8. Sandoz International GmbH (Switzerland)
      • 15.2.9. Teva Pharmaceuticals Industries Ltd. (Israel)
  16. Research Methodology

  17. Key Assumptions and Acronyms

  • Amgen Inc. (U.S.)
  • Biocon Ltd. (India)
  • Celltrion, Inc. (South Korea)
  • Dr. Reddys Laboratories Ltd. (India)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer Inc. (U.S.)
  • Samsung Bioepis (South Korea)
  • Novatis AG (Switzerland)
  • Teva Pharmaceuticals Industries Ltd. (Israel)

Adjacent Markets